Indian Pharma companies have brought a pioneering change by being one of the largest contributions in the world. The bulk production at an economical cost and its seamless process in exporting has drawn a lot of attention from many other countries.
As India is prepping to supply Covid-19 vaccines even to “not-so-friendly nations”, the Delhi High Court on Wednesday advised the Center that it needs to prove its goodwill inside the nation first and afterward acquire it outside.
The statement was made by the division bench of Justices Vipin Sanghi and Rekha Palli during the knowing about a suo motu appeal in regards to the PIL by legal advisors for immunization of all individuals from the legal executive, including judges, court staff, and advocates.
Solicitor General of India, Tushar Mehta argued before the court that the government has given prioritization for vaccination drive on the basis of age, vulnerability and co-morbidity but not profession.
The bench stated that government is sensitive to the requirements of the citizens. The bench observed- “Mr Mehta, today’s newspapers show that you are exporting to not-so-friendly countries also… that will deprive the Indian population… earn the goodwill within the country and then earn it outside.”
The Centre made the submission in response to a PIL initiated by the high court to analyse the demand to declare all people related to the judicial functioning, including judges, court staff and lawyers, as “frontline workers” in order to make COVID-19 vaccination available on priority and without limitations of their age or physical condition.